top of page
CSPC starts P2 Type-2 diabetes weight-loss study
CSPC Pharma
16/09/26
CSPC has started patient recruitment into its Phase 2 study of SYH2069 injection to treat Type-2 diabetes mellitus. SYH2069 is a fatty acid-modified polypeptide, and dual agonist of GLP-1R and GIPR. The product is designed to promote insulin secretion, but also expected to suppress appetite, delay gastric emptying, increase satiation relating to weight-loss effects.
IASO208 CAR-T receives FDA IND clearance
IASO Bio
16/09/26
The US FDA has cleared the IND for IASO208 CD20-targeting CAR-T therapy. IASO208 uses a lentivial vector to deliver humanised anti-CD20 CAR transgene, to generate anti-CD20 CAR-T cells. IASO208 is currently in a Phase 1 study in China to assess safety, tolerability, and early efficacy in patients with relapsed/refractory B-cell malignancies.
Chimagen sells oncology trispecific to GSK for USD750m
Chimagen
15/09/26
GSK has acquired the global rights to Chimagen’s trispecfic T cell-engager to treat multiple myeloma for up to USD750m in upfront, development and commercial milestone payments. The asset is engineered to bind to T cells plus two strategically selected tumour-associated antigens. GSK plans to take the product in the Phase 1 trials in 2027.
Kelun publishes P3 data in JCO
Kelun-Biotech
14/09/26
Results from Kelun’s Phase 3 study of trastuzumab botidotin to treat HER-2 positive unresectable or metastatic breast cancer are now published in the Journal of Clinical Oncology (JCO). The study showed that trastuzumab botidotin monotherapy significantly prolonged progression free survival over trastuzumab emtansine.
MediLink lung cancer drug significantly extends overall survival
MediLink
13/09/26
Tambotatug Pelitecan (Tam-Peli), an anti-B7-H3 ADC from MediLink, met its primary endpoint of overall survival, and demonstrated a 54% reduction in the risk of death. Tam-Peli also significantly extended progression free survival. The new data was generated in a P3 study of Tam-Peli vs Topotecan chemotherapy, in small cell lung cancer patients that had disease progression following platinum-based chemo. The trial enrolled 451 patients across 85 sites in China. Roche has exclusive commercialisation rights to Tam-Peli outside of China, Hong Kong, and Macau.
CMS receives approval for systemic lupus product trial
China Medical Systems
11/09/26
CMS was granted Drug Clinical Trial Approval Notice from China’s NMPA for CMS-D001 to treat systemic lupus erthematosus. CMS-D001 is an oral inhibitor of TYK2, and member of the JAK family. CMS proposes that, compared to pan-JAK inbibitors, CMS-D001 is more selective and has the potential to reduce side effects and without risk of anti-drug antibody formation
OcuMension NDA accepted for NMPA review
OcuMension Therapeutics
11/09/26
OcuMension’s NCX 470 (OT-301), to lower intraocular pressure in patients with open-angel glaucoma or ocular hypertensions, has its NDA accepted for review by the NMPA. OcuMension has commercialisation rights to the product – from Nicox – in China, Korea, and South East Asia.
Adagene partner Third Arc selects first drug candiate
Adagene
10/09/26
Adagene’s partner Third Arc Bio has selected its first antibody drug development candidate from Adagene’s SAFEbody platform. Under an agreement from November 2025, Adagene is providing Masked CD3 T cell antibodies targeting epitopes of tumour-associated antigens.
Positive P2a data on Rifaquizinone for periprosthetic joint infection
TenNor Therapeutics
10/09/26
TenNor’s topline results from its Phase 2a rifaquizinone (TNP-2092) provided proof-of-concept of the product’s potential to treat Periprosthetic Joint Infection (PJI) without surgical intervention. Rifaquizinone is a first-in-class, triple-targeting anti-infective addressing implant-associated biofilm infections.
Transcenta and WuXi Biologics to commercialse bioprocessing tech
Transcenta Therapeutics
09/09/26
Transcenta granted WuXi a non-exclusive license to its bioprocessing platform and cell culture media for RMB10m (USD1.5m). Transcenta has a pipeline of clinical and preclinical stage oncology products, plus products in osteoporosis and other auto-immune diseases
InnoCare IND approved for bispecific for prostate cancer
InnoCare
08/09/26
InnoCare received NMPA (China’s National Medical Products Administration) approval of its IND for ICP-B382, bispecific ADC targeting PSMA and STEAP1 for the treatment of solid tumours including prostate cancer. This is InnoCare’s first bispecific ADC to enter clinical studies. ICP-B381 is targeting PSMA and STEAP1 as they are significantly overexpressed in prostate cancer cells with limited expression in normal tissue, making them highly promising therapeutic targets.
Interim P3 analysis of Ivonescimab shows meaningful benefit in lung cancer
Akeso
03/09/26
Interim data from Akeso’s Phase 3 HARMONi-2 study of ivonescimab PD-1/VEGF bispecific antibody demonstrated a statistically significant and clinically meaningful improvement over Pembrolizumab in non-small cell lung cancer with tumours expressing PD-L1.
Hansoh gets BLA for cancer drug
Hansoh Pharma
09/07/26
Hansoh Pharma says the China National Medical Products Administration (NMPA）has accepted its biologics license application (BLA) for HS-20093（Risvutatug rezetecan, or Ris-Rez）injectable to treat small cell lung cancer (SCLC). Ris-Rez is a B7-H3-targeted antibody-drug conjugate (ADC) under clinical development for multiple solid tumors. The BLA is supported by results from a pivotal Phase 3 clinical trial (ARTEMIS-008) for patients with advanced or relapsed SCLC after prior platinum-based therapy.
bottom of page